An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
Status:
Unknown status
Trial end date:
2021-06-15
Target enrollment:
Participant gender:
Summary
This is an open-label study to evaluate the safety and the anti-tumor activity of the
combination of nivolumab and celecoxib.
The total numbers of participants to be enrolled will be up to 68 participants, depending on
the investigated dose of celecoxib during the safety run-in phase.
Phase:
Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain